NCT04728425View on ClinicalTrials.gov

Subcutaneous Immunoglobulin for Myasthenia Gravis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

December 30, 2023

Conditions
Myasthenia Gravis
Interventions
DRUG

subcutaneous immunoglobulin (SCIG)

20% subcutaneous immunoglobulin

DRUG

intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG)

10% intravenous immunoglobulin + 20% subcutaneous immunoglobulin

Trial Locations (1)

M5G 2C4

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT04728425 - Subcutaneous Immunoglobulin for Myasthenia Gravis | Biotech Hunter | Biotech Hunter